Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis

T. Hibi, M. Ohara, M. Watanabe, T. Kanai, H. Takaishi, A. Hayashi, Y. Hosoda, H. Ogata, Y. Iwao, Sadakazu Aiso, N. Watanabe, K. Toda, M. Tsuchiya

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

In vitro effects of cytokines and therapeutic drugs on antibody dependent cellular cytotoxicity (ADCC) mediated by anticolon antibody were investigated in serum samples from patients with ulcerative colitis. A 51Cr release assay was used to examine ADCC activity with the colon cancer cell line, colo 205, as the target and peripheral blood mononuclear cells as the effector. High ADCC activity was shown in 13 of 32 (41%) patients with ulcerative colitis. This ADCC activity was inhibited by protein A treatment of the serum samples. Interleukin 2 (IL2) activated effector cells could enhance ADCC activity, but interferon-γ (IFN-γ) or tumour necrosis factor-α (TNF-α) had no effect on the cytotoxic activity of effector cells. Treatment of target cells with IFN-γ increased the vulnerability of these cells to ADCC with a large increase of intercellular adhesion molecule-1 (ICAM-1) expression on their surface. Monoclonal antibodies to ICAM-1 inhibited this IFN-γ enhanced ADCC activity. Interestingly, prednisolone (PSL) reduced ADCC activity, but sulphasalazine (SASP) or 5-aminosalicylic acid (5-ASA) did not. These results suggest that IL2 and IFN-γ could enhance colinic epithelial cell injury mediated by the ADCC mechanism in ulcerative colitis and that ADCC enhanced by cytokines is restored by PSL treatment.

Original languageEnglish
Pages (from-to)788-793
Number of pages6
JournalGut
Volume34
Issue number6
DOIs
Publication statusPublished - 1993 Jan 1
Externally publishedYes

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Hibi, T., Ohara, M., Watanabe, M., Kanai, T., Takaishi, H., Hayashi, A., ... Tsuchiya, M. (1993). Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. Gut, 34(6), 788-793. https://doi.org/10.1136/gut.34.6.788

Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. / Hibi, T.; Ohara, M.; Watanabe, M.; Kanai, T.; Takaishi, H.; Hayashi, A.; Hosoda, Y.; Ogata, H.; Iwao, Y.; Aiso, Sadakazu; Watanabe, N.; Toda, K.; Tsuchiya, M.

In: Gut, Vol. 34, No. 6, 01.01.1993, p. 788-793.

Research output: Contribution to journalArticle

Hibi, T, Ohara, M, Watanabe, M, Kanai, T, Takaishi, H, Hayashi, A, Hosoda, Y, Ogata, H, Iwao, Y, Aiso, S, Watanabe, N, Toda, K & Tsuchiya, M 1993, 'Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis', Gut, vol. 34, no. 6, pp. 788-793. https://doi.org/10.1136/gut.34.6.788
Hibi, T. ; Ohara, M. ; Watanabe, M. ; Kanai, T. ; Takaishi, H. ; Hayashi, A. ; Hosoda, Y. ; Ogata, H. ; Iwao, Y. ; Aiso, Sadakazu ; Watanabe, N. ; Toda, K. ; Tsuchiya, M. / Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis. In: Gut. 1993 ; Vol. 34, No. 6. pp. 788-793.
@article{3d22da3449ef41189a71a52c1119897d,
title = "Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis",
abstract = "In vitro effects of cytokines and therapeutic drugs on antibody dependent cellular cytotoxicity (ADCC) mediated by anticolon antibody were investigated in serum samples from patients with ulcerative colitis. A 51Cr release assay was used to examine ADCC activity with the colon cancer cell line, colo 205, as the target and peripheral blood mononuclear cells as the effector. High ADCC activity was shown in 13 of 32 (41{\%}) patients with ulcerative colitis. This ADCC activity was inhibited by protein A treatment of the serum samples. Interleukin 2 (IL2) activated effector cells could enhance ADCC activity, but interferon-γ (IFN-γ) or tumour necrosis factor-α (TNF-α) had no effect on the cytotoxic activity of effector cells. Treatment of target cells with IFN-γ increased the vulnerability of these cells to ADCC with a large increase of intercellular adhesion molecule-1 (ICAM-1) expression on their surface. Monoclonal antibodies to ICAM-1 inhibited this IFN-γ enhanced ADCC activity. Interestingly, prednisolone (PSL) reduced ADCC activity, but sulphasalazine (SASP) or 5-aminosalicylic acid (5-ASA) did not. These results suggest that IL2 and IFN-γ could enhance colinic epithelial cell injury mediated by the ADCC mechanism in ulcerative colitis and that ADCC enhanced by cytokines is restored by PSL treatment.",
author = "T. Hibi and M. Ohara and M. Watanabe and T. Kanai and H. Takaishi and A. Hayashi and Y. Hosoda and H. Ogata and Y. Iwao and Sadakazu Aiso and N. Watanabe and K. Toda and M. Tsuchiya",
year = "1993",
month = "1",
day = "1",
doi = "10.1136/gut.34.6.788",
language = "English",
volume = "34",
pages = "788--793",
journal = "Gut",
issn = "0017-5749",
publisher = "BMJ Publishing Group",
number = "6",

}

TY - JOUR

T1 - Interleukin 2 and interferon-γ augment anticolon antibody dependent cellular cytotoxicity in ulcerative colitis

AU - Hibi, T.

AU - Ohara, M.

AU - Watanabe, M.

AU - Kanai, T.

AU - Takaishi, H.

AU - Hayashi, A.

AU - Hosoda, Y.

AU - Ogata, H.

AU - Iwao, Y.

AU - Aiso, Sadakazu

AU - Watanabe, N.

AU - Toda, K.

AU - Tsuchiya, M.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - In vitro effects of cytokines and therapeutic drugs on antibody dependent cellular cytotoxicity (ADCC) mediated by anticolon antibody were investigated in serum samples from patients with ulcerative colitis. A 51Cr release assay was used to examine ADCC activity with the colon cancer cell line, colo 205, as the target and peripheral blood mononuclear cells as the effector. High ADCC activity was shown in 13 of 32 (41%) patients with ulcerative colitis. This ADCC activity was inhibited by protein A treatment of the serum samples. Interleukin 2 (IL2) activated effector cells could enhance ADCC activity, but interferon-γ (IFN-γ) or tumour necrosis factor-α (TNF-α) had no effect on the cytotoxic activity of effector cells. Treatment of target cells with IFN-γ increased the vulnerability of these cells to ADCC with a large increase of intercellular adhesion molecule-1 (ICAM-1) expression on their surface. Monoclonal antibodies to ICAM-1 inhibited this IFN-γ enhanced ADCC activity. Interestingly, prednisolone (PSL) reduced ADCC activity, but sulphasalazine (SASP) or 5-aminosalicylic acid (5-ASA) did not. These results suggest that IL2 and IFN-γ could enhance colinic epithelial cell injury mediated by the ADCC mechanism in ulcerative colitis and that ADCC enhanced by cytokines is restored by PSL treatment.

AB - In vitro effects of cytokines and therapeutic drugs on antibody dependent cellular cytotoxicity (ADCC) mediated by anticolon antibody were investigated in serum samples from patients with ulcerative colitis. A 51Cr release assay was used to examine ADCC activity with the colon cancer cell line, colo 205, as the target and peripheral blood mononuclear cells as the effector. High ADCC activity was shown in 13 of 32 (41%) patients with ulcerative colitis. This ADCC activity was inhibited by protein A treatment of the serum samples. Interleukin 2 (IL2) activated effector cells could enhance ADCC activity, but interferon-γ (IFN-γ) or tumour necrosis factor-α (TNF-α) had no effect on the cytotoxic activity of effector cells. Treatment of target cells with IFN-γ increased the vulnerability of these cells to ADCC with a large increase of intercellular adhesion molecule-1 (ICAM-1) expression on their surface. Monoclonal antibodies to ICAM-1 inhibited this IFN-γ enhanced ADCC activity. Interestingly, prednisolone (PSL) reduced ADCC activity, but sulphasalazine (SASP) or 5-aminosalicylic acid (5-ASA) did not. These results suggest that IL2 and IFN-γ could enhance colinic epithelial cell injury mediated by the ADCC mechanism in ulcerative colitis and that ADCC enhanced by cytokines is restored by PSL treatment.

UR - http://www.scopus.com/inward/record.url?scp=0027322328&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027322328&partnerID=8YFLogxK

U2 - 10.1136/gut.34.6.788

DO - 10.1136/gut.34.6.788

M3 - Article

VL - 34

SP - 788

EP - 793

JO - Gut

JF - Gut

SN - 0017-5749

IS - 6

ER -